The latest announcement is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Limited has updated the terms of reference for its Nomination Committee, which is responsible for identifying and recommending candidates for the company’s board of directors. The committee, comprising a majority of independent non-executive directors, plays a crucial role in overseeing board performance and developing nomination guidelines in line with applicable laws and listing standards. This update aims to enhance the governance structure of the company, potentially impacting its strategic decision-making and stakeholder confidence.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the areas of oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases. The company is listed on the Hong Kong Stock Exchange and is committed to addressing unmet medical needs in Asia and other emerging markets.
YTD Price Performance: 34.61%
Average Trading Volume: 5,463,469
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.46B
For detailed information about 1952 stock, go to TipRanks’ Stock Analysis page.